Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-ING-41 with gemcitabine and docetaxel in advanced sarcomas
NCT04906876Phase 2Withdrawn
- Sponsor
- Brown University
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elraglusib in soft tissue sarcoma (STS), bone sarcoma, sponsored by Brown University. Planned start Sep 2021; status: withdrawn.
02
Drugs
elraglusib
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT04906876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906876.